Glaukos Co. (NYSE:GKOS) Shares Acquired by Caldwell Sutter Capital Inc.

Caldwell Sutter Capital Inc. lifted its stake in shares of Glaukos Co. (NYSE:GKOS) by 5,860.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,490 shares of the medical instruments supplier’s stock after buying an additional 1,465 shares during the period. Caldwell Sutter Capital Inc.’s holdings in Glaukos were worth $140,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. National Bank of Canada FI acquired a new position in Glaukos during the fourth quarter valued at $46,000. GAMMA Investing LLC acquired a new position in Glaukos during the fourth quarter valued at $55,000. Quadrant Capital Group LLC lifted its position in Glaukos by 54.8% during the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after purchasing an additional 329 shares during the period. Fisher Asset Management LLC acquired a new position in Glaukos during the fourth quarter valued at $216,000. Finally, Aigen Investment Management LP acquired a new position in Glaukos during the fourth quarter valued at $228,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Price Performance

NYSE GKOS traded up $0.31 during trading hours on Wednesday, hitting $119.29. 265,106 shares of the company’s stock traded hands, compared to its average volume of 594,882. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $121.04. The company has a quick ratio of 4.68, a current ratio of 5.38 and a debt-to-equity ratio of 0.78. The firm’s 50-day moving average is $109.95 and its 200-day moving average is $96.91.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.12). The business had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $79.60 million. Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The firm’s revenue was up 15.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.59) EPS. As a group, research analysts anticipate that Glaukos Co. will post -2.24 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,500 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $113.50, for a total value of $283,750.00. Following the transaction, the chief operating officer now directly owns 101,845 shares in the company, valued at approximately $11,559,407.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Alex R. Thurman sold 1,372 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $100.54, for a total value of $137,940.88. Following the transaction, the chief financial officer now directly owns 52,532 shares in the company, valued at approximately $5,281,567.28. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $113.50, for a total transaction of $283,750.00. Following the completion of the transaction, the chief operating officer now owns 101,845 shares in the company, valued at $11,559,407.50. The disclosure for this sale can be found here. Insiders have sold 81,001 shares of company stock worth $8,344,878 in the last ninety days. 6.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. BTIG Research upped their price objective on shares of Glaukos from $107.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. JPMorgan Chase & Co. upped their price objective on shares of Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Truist Financial reiterated a “buy” rating and issued a $125.00 price objective (up previously from $120.00) on shares of Glaukos in a research report on Thursday, May 2nd. Wells Fargo & Company upped their price objective on shares of Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, June 3rd. Finally, Stifel Nicolaus boosted their target price on shares of Glaukos from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, June 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $112.27.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.